Last Update: Aug 12, 2026 A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes: Victorion - RIDES ClinicalTrials.gov Identifier: [NCT07102628](https://clinicaltrials.gov/ct2/show/NCT07102628) Novartis Reference Number:CKJX839A12309 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment. This is a multicenter, prospective, randomized, double-blind, placebo-controlled, two arms, parallel groups clinical trial in participants experiencing an ACS (STEMI or NSTEMI) of recent onset. The study drug treatment (inclisiran/placebo) will be initiated at randomization (Day 1) and before discharge. The study consists of: 1\. Screening visit within 7 days (≤ 7 days) from hospital admission. Screening visit might happen at hospital admission day or any time after hospital admission and before randomization (Day 1). 2\. Randomization/Baseline visit (Day 1) within 7 days (≤ 7 days) from hospital admission and before or at day of discharge. The discharge can happen any time after randomization and first study drug administration (Day 1). 3\. Double-blinded treatment period (150 days). 4\. Scheduled safety calls in between visits during the double-blind treatment period (they do not replace on-site visits) 5\. Safety Follow-up call (30 days after EOS visit) Screening and randomization visits must happen during the in-hospital phase, within 7 days (≤ 7 days), and before discharge. The Screening period, of no more than 6 days after the date of hospital admission, will be used to determine if patients qualify to enter the double-blind treatment phase of the study. Screening and Randomization/Day 1 visits cannot occur on the same day. The overall study duration is 150 days. Condition Acute Coronary Syndrome Phase Phase3 Overall Status Recruiting Number of Participants300 Start Date Oct 03, 2025 Completion Date Feb 11, 2027 Gender All Age(s) 18 Years - (Adult, Older Adult) ## Interventions Drug ### Inclisiran The participants will receive Inclisiran sodium 300 mg subcutaneous at randomization (Day 1, Baseline visit) and Day 90 Drug ### Placebo The participants will receive placebo subcutaneous at randomization (Day 1, Baseline visit) and Day 90 ## Eligibility Criteria Inclusion Criteria: Participant eligible for inclusion in this study must meet all the following criteria: At Screening: 1\. Signed informed consent must be obtained prior to participation in the study. 2\. Males and females, ≥18 years of age at the time of providing written informed consent. 3\. Ability to understand study's requirements and provide informed consent and comply with all required study procedures. 4\. Hospitalization for a ACS event (STEMI or NSTEMI). 5\. Receiving treatment for the qualifying ACS event, according to clinical judgement, by means of medical treatment alone or percutaneous coronary revascularization. 6\. Had a successful PCI (with or without stent) for the qualifying event if a PCI was required. 7\. LDL-C value at the Screening visit measured by the local lab of: \* LDL-C ≥70 mg/dL in participant previously treated with high-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day) or equivalent as per national guidelines and local regulation for at least 4 weeks before screening or \* LDL-C ≥100 mg/dL in participant previously treated with low/moderate-intensity statin for at least 4 weeks before screening or \* LDL-C ≥125 mg/dL in participant previously not treated with statins for at least 4 weeks before screening, or who never received statins (including statin intolerant participants). At Randomization: 8\. The participant must have a Baseline fasting LDL-C ≥70 mg/dL (local lab assessment) to be eligible for randomization. 9\. Randomization within 7 days (≤ 7 days) following hospital admission for the qualifying ACS event and before/at discharge. Exclusion Criteria: Participant meeting any of the following criteria is not eligible for inclusion in this study. Only for Japan: For exclusion criteria 6, investigator judgment should be documented in the source data document. 1\. Participant who is clinically unstable during hospitalization for the qualifying ACS event, defined by any of the following events within 24 hours prior to randomization: \* Hemodynamic instability: hypotension, defined as sustained systolic blood pressure of \\<90 mmHg due to cardiac failure with associated symptoms requiring inotropes \* Arrhythmic events: Ventricular storm (e.g., torsade, ventricular tachycardia, ventricular flutter) \* Cardiogenic shock or mechanical complication of myocardial infarction \* New York Heart Association (NYHA) class IV heart failure \* Left ventricular ejection fraction \\<20% at randomization (after all treatment procedures, based on the latest assessment of the LVEF using invasive or non-invasive assessment modalities) \* Uncontrolled severe hypertension: systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg prior to randomization despite antihypertensive therapy. 2\. Participant who has undergone or is scheduled to undergo CABG for treatment of the qualifying ACS event. 3\. Active liver disease defined as: (i) any known current infectious, neoplastic, or metabolic pathology of the liver or (ii) alanine aminotransferase (ALT) elevation \\>3x ULN or aspartate aminotransferase (AST) elevation \\>3x ULN, or total bilirubin elevation \\>2x ULN (except participant with Gilbert's syndrome) at the Screening visit, in the context of an ACS, and assessed as related to the index event and/or treatment procedures (such as PCI). Eligibility will be based on Investigator's judgement for participant who will be randomized. 4\. Renal insufficiency (eGFR \\<30 mL/min/1.73m2) at the Screening visit. 5\. Fasting triglycerides value \\>400 mg/dL (4.52 mmol/L; assessed by local labs) at randomization visit. 6\. Participant, who based on the Investigator's judgement, could reach the LDL-C target value of \\<55 mg/dL after 4 weeks on statin treatment only. 7\. Secondary hypercholesterolemia (based on medical history). 8\. Homozygous familial hypercholesterolemia (based on medical history). 9\. Participant on apheresis at the Screening visit. 10\. Ongoing or medical history of myopathy at the Screening visit. 11\. CK values ≥5x ULN at Screening visit and confirmed by repeat test during Screening (local lab) , in the context of an ACS, and assessed as related to the index event and/or treatment procedures (such as PCI) eligibility will be based on Investigator's judgement for participant who will be randomized (who will be switched to or initiated on the protocol-specified dose of high-intensity statin of atorvastatin ≥40 mg QD or rosuvastatin ≥20 mg QD). Unless a more stringent CK value threshold is mandated by a local regulatory authority (e.g., ≥3x ULN in Korea according to MFDS internal guideline). Argentina #### Novartis Investigative Site Recruiting Capital Federal,Buenos Aires,B1406,Argentina Australia #### Novartis Investigative Site Recruiting Garran,Australian Capital Territory,2605,Australia #### Novartis Investigative Site Recruiting Clayton,Victoria,3168,Australia Canada #### Novartis Investigative Site Recruiting Newmarket,Ontario,J7y 2p9,Canada #### Novartis Investigative Site Recruiting London,Ontario,N6a 5w9,Canada #### Novartis Investigative Site Recruiting Edmonton,Alberta,T6g 2b7,Canada #### Novartis Investigative Site Recruiting Montreal,Quebec,H1t 1c8,Canada #### Novartis Investigative Site Recruiting Québec,Quebec,G1v 4g5,Canada China #### Novartis Investigative Site Recruiting Beijing,China,100037,China #### Novartis Investigative Site Recruiting Tianjin,300052,China #### Novartis Investigative Site Recruiting Jining,272011,China #### Novartis Investigative Site Recruiting Guangzhou,510260,China #### Novartis Investigative Site Recruiting Beijing,100730,China #### Novartis Investigative Site Recruiting Beijing,100191,China #### Novartis Investigative Site Recruiting Nanchang,Jiangxi,330009,China #### Novartis Investigative Site Recruiting Guangzhou,Guangdong,510080,China #### Novartis Investigative Site Recruiting Fuzhou,350001,China #### Novartis Investigative Site Recruiting Guangzhou,510280,China #### Novartis Investigative Site Recruiting Xuzhou,Jiangsu,221003,China #### Novartis Investigative Site Recruiting Shanghai,200120,China #### Novartis Investigative Site Recruiting Shanghai,200032,China #### Novartis Investigative Site Recruiting Wenzhou,Zhejiang,325000,China #### Novartis Investigative Site Recruiting Luoyang,Henan,471002,China France #### Novartis Investigative Site Recruiting Poitiers,86021,France #### Novartis Investigative Site Recruiting Nantes,44093,France #### Novartis Investigative Site Recruiting Chambray-lès-Tours,37170,France #### Novartis Investigative Site Recruiting Montpellier,34295,France #### Novartis Investigative Site Recruiting Pessac,33604,France Germany #### Novartis Investigative Site Recruiting Coburg,96450,Germany #### Novartis Investigative Site Recruiting Kiel,24105,Germany #### Novartis Investigative Site Recruiting Erfurt,99089,Germany #### Novartis Investigative Site Recruiting Hennigsdorf,16761,Germany #### Novartis Investigative Site Recruiting Leipzig,Saxony,04289,Germany #### Novartis Investigative Site Recruiting Essen,45147,Germany Hong Kong #### Novartis Investigative Site Recruiting Hong Kong,Hong Kong,999077,Hong Kong Hungary #### Novartis Investigative Site Recruiting Budapest,1083,Hungary #### Novartis Investigative Site Recruiting Miskolc,3526,Hungary #### Novartis Investigative Site Recruiting Budapest,1134,Hungary #### Novartis Investigative Site Recruiting Debrecen,Hajdu Bihar Megye,4032,Hungary #### Novartis Investigative Site Recruiting Pécs,Baranya,7623,Hungary India #### Novartis Investigative Site Recruiting Belagavi,Karnataka,590010,India #### Novartis Investigative Site Recruiting Nashik,Maharashtra,422005,India #### Novartis Investigative Site Recruiting Bikaner,Rajasthan,334003,India #### Novartis Investigative Site Recruiting Mumbai,Maharashtra,400012,India Poland #### Novartis Investigative Site Recruiting Opole,45-401,Poland #### Novartis Investigative Site Recruiting Katowice,40-635,Poland #### Novartis Investigative Site Recruiting Gdansk,80-214,Poland #### Novartis Investigative Site Recruiting Krakow,31 202,Poland South Korea #### Novartis Investigative Site Recruiting Seoul,Seoul,06351,South Korea #### Novartis Investigative Site Recruiting Seoul,07804,South Korea Spain #### Novartis Investigative Site Recruiting Salamanca,37007,Spain #### Novartis Investigative Site Recruiting Seville,41013,Spain #### Novartis Investigative Site Recruiting Valencia,46010,Spain #### Novartis Investigative Site Recruiting Madrid,28046,Spain #### Novartis Investigative Site Recruiting Madrid,28034,Spain #### Novartis Investigative Site Recruiting Las Palmas GC,35010,Spain #### Novartis Investigative Site Recruiting El Palmar,Murcia,30120,Spain #### Novartis Investigative Site Recruiting Huelva,Andalusia,21005,Spain #### Novartis Investigative Site Recruiting Santiago Compostela,A Coruna,15706,Spain Switzerland #### Novartis Investigative Site Recruiting Geneva,1211,Switzerland #### Novartis Investigative Site Recruiting Lucerne,6000,Switzerland #### Novartis Investigative Site Recruiting Bern,3010,Switzerland ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +81337978748](tel:+81337978748) Email: [](mailto:) #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: